product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
EGF Receptor (D38B1) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate)
catalog :
5616
clonality :
monoclonal
host :
domestic rabbit
conjugate :
AF488
clone name :
D38B1
reactivity :
human, mouse
application :
immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 28
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 7a
Coy S, Wang S, Stopka S, Lin J, Yapp C, Ritch C, et al. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022;13:4814 pubmed publisher
  • immunohistochemistry - paraffin section; human
  • immunohistochemistry; human
Lin J, Izar B, Wang S, Yapp C, Mei S, Shah P, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. elife. 2018;7: pubmed publisher
Liu X, Kano M, Araki T, Cooper O, Fukuoka H, Tone Y, et al. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology. 2015;156:71-9 pubmed publisher
Schiefler C, Piontek G, Doescher J, Schuettler D, Mißlbeck M, Rudelius M, et al. Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk. Oncotarget. 2014;5:9877-88 pubmed
Cheng H, Ballman K, Vassilakopoulou M, Dueck A, Reinholz M, Tenner K, et al. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer. 2014;111:1065-71 pubmed publisher
Pickhard A, Siegl M, Baumann A, Huhn M, Wirth M, Reiter R, et al. The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism. Oncotarget. 2014;5:5428-38 pubmed
Algars A, Avoranta T, Osterlund P, Lintunen M, Sundström J, Jokilehto T, et al. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS ONE. 2014;9:e99590 pubmed publisher
Yoshiya S, Fujimoto Y, Bekki Y, Konishi H, Yamashita Y, Ikegami T, et al. Impact of epidermal growth factor single-nucleotide polymorphism on recurrence of hepatocellular carcinoma after hepatectomy in patients with chronic hepatitis C virus infection. Cancer Sci. 2014;105:646-50 pubmed publisher
Wattenberg M, Kwilas A, Gameiro S, Dicker A, Hodge J. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer. 2014;110:1472-80 pubmed publisher
Colin S, Darne B, Kadi A, Ferry A, Favier M, Lesaffre C, et al. The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3?-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients. J Pharmacol Exp Ther. 2014;349:107-17 pubmed publisher
Jiang A, Zhou D, Meng X, Zhang A, Zhang C, Li X, et al. Down-regulation of epidermal growth factor receptor by curcumin-induced UBE1L in human bronchial epithelial cells. J Nutr Biochem. 2014;25:241-9 pubmed publisher
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21 Suppl 4:S490-6 pubmed publisher
Stratmann A, Fecher D, Wangorsch G, Göttlich C, Walles T, Walles H, et al. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol Oncol. 2014;8:351-65 pubmed publisher
Slanina H, Mündlein S, Hebling S, Schubert Unkmeir A. Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells. Infect Immun. 2014;82:1243-55 pubmed publisher
Rybak A, Tang D. SOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells. Cell Signal. 2013;25:2734-42 pubmed publisher
Foerster S, Kacprowski T, Dhople V, Hammer E, Herzog S, Saafan H, et al. Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics. Proteomics. 2013;13:3131-44 pubmed publisher
Tardáguila M, Mira E, García Cabezas M, Feijoo A, Quintela Fandino M, Azcoitia I, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 2013;73:4461-73 pubmed publisher
Han C, Yue L, Tai L, Zhou L, Li X, Xing G, et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro. Int J Nanomedicine. 2013;8:1541-9 pubmed publisher
Janjigian Y, Viola Villegas N, Holland J, Divilov V, Carlin S, Gomes Dagama E, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-43 pubmed publisher
Kuo H, Chen Y, Chang H, Jeng J, Lin E, Pan C, et al. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer. Carcinogenesis. 2013;34:1708-16 pubmed publisher
Jiang G, Fan C, Zhang X, Dong Q, Wang L, Liu Y, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS ONE. 2013;8:e59183 pubmed publisher
Masumoto K, Tsukimoto M, Kojima S. Role of TRPM2 and TRPV1 cation channels in cellular responses to radiation-induced DNA damage. Biochim Biophys Acta. 2013;1830:3382-90 pubmed publisher
Gellersen B, Wolf A, Kruse M, Schwenke M, Bamberger A. Human endometrial stromal cell-trophoblast interactions: mutual stimulation of chemotactic migration and promigratory roles of cell surface molecules CD82 and CEACAM1. Biol Reprod. 2013;88:80 pubmed publisher
Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE. 2012;7:e41017 pubmed publisher
Koga H, Tsedensodnom O, Tomimaru Y, Walker E, Lee H, Kim K, et al. Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS ONE. 2012;7:e39981 pubmed publisher
Rimkunas V, Crosby K, Li D, Hu Y, Kelly M, Gu T, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-57 pubmed publisher
Xu B, Chen H, Xu W, Zhang W, Buckley S, Zheng S, et al. Molecular mechanisms of MMP9 overexpression and its role in emphysema pathogenesis of Smad3-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2012;303:L89-96 pubmed publisher
Cihil K, Ellinger P, Fellows A, Stolz D, Madden D, Swiatecka Urban A. Disabled-2 protein facilitates assembly polypeptide-2-independent recruitment of cystic fibrosis transmembrane conductance regulator to endocytic vesicles in polarized human airway epithelial cells. J Biol Chem. 2012;287:15087-99 pubmed publisher
product information
SKU :
5616S
Product-Name :
EGF Receptor (D38B1) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate)
Size :
100 ul
Price-(USD) :
321 USD
Product-Category :
RTK
Shipping-Temp :
COLD
Storage-Temp :
4°C
Product-Type :
Monoclonal Antibody
Host :
Rabbit
Target :
EGFR
Primary-Protein :
EGFR
Alt-Names :
EGFR,ERBB,ERBB1,Epidermal growth factor receptor,HER1,PIG61,Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1,avian erythroblastic leukemia viral (v-erb-b) oncogene homolog,cell growth inhibiting protein 40,cell proliferation-inducing protein 61,epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian),mENA
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.